Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | DRD3 | P35462 | 5/20 | 0.44 |
| ▸ | DRD4 | P21917 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6343814 | 0.89 | ALDH1A1 (0.51) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 | |
| SCHEMBL6334435 | 0.88 | DRD2 (0.62) | CYP2D6DRD2DRD3DRD4 | |
| SCHEMBL6344935 | 0.88 | DRD3 (0.62) | DRD2DRD3DRD4 | |
| SCHEMBL3388549 | 0.87 | ALDH1A1 (0.49) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 | |
| SCHEMBL6336486 | 0.87 | ALDH1A1 (0.49) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 | |
| SCHEMBL6334373 | 0.87 | ALDH1A1 (0.49) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 | |
| SCHEMBL6344274 | 0.86 | ALDH1A1 (0.48) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 | |
| SCHEMBL6337152 | 0.85 | ALDH1A1 (0.47) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 | |
| SCHEMBL6340997 | 0.85 | ALDH1A1 (0.47) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 | |
| SCHEMBL6338499 | 0.81 | GAA (0.52) | ALDH1A1CYP2D6CYP2C9ALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864266-B2 | 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1453805-A1 | 4-PIPERIDINYL ALKYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| US-20040092554-A1 | 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists | BROTHERTON-PLEISS CHRISTINE E (US) | 2004-05-13 | — | — | US | disclosed |
| US-6627644-B2 | Muscarinic receptor antagonists and parasympathetic nervous system. The physiological actions of Acetylcholine are mediated by activation of either nicotinic or muscarinic receptors | SYNTEX (U.S.A.) LLC | 2003-09-30 | — | — | US | disclosed |
| US-20030162780-A1 | 4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | SYNTEX (U.S.A.) LLC, NAME CHANGED TO ROCHE PALO ALTO LLC | 2003-08-28 | — | — | US | disclosed |
| WO-2003048124-A1 | 4-PIPERIDINYL ALKYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162780-A1 | 4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM1, CHRM3, CHRM2 | ALDH1A1 1115/4885CYP2D6 613/4885CYP2C9 1052/4885 |
| US-20040092554-A1 | 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists | CHRM1, CHRM3, CHRM2 | ALDH1A1 1115/4885CYP2D6 613/4885CYP2C9 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.